Acadia Healthcare, the largest stand-alone behavioral healthcare operator in the United States, reported its fiscal second quarter against the backdrop of a decade-long accumulation of legal storms and a Medicaid reform bill that reaches directly into its biggest payor. There are two ways to read this quarter, and neither is the headline. The headline was weak: revenue flat, GAAP earnings per share down to $0.12 from $0.33, adjusted earnings per share down more than half. But most of the decline is accounting and contingency, not operations. Underlying demand was genuinely firm - patient days rose, admissions rose 6.4%, same-facility revenue grew 3.2% once the timing of periodic supplemental state payments is stripped out, and normalized total revenue grew 2.8%. The company exited the quarter with sharply stronger cash flow, raised its full-year revenue, adjusted EBITDA, and cash-flow guidance, and narrowed its adjusted EPS range.
The weakness, and the risk, is the long shadow of the law. Q2 absorbed a $28.6 million boost to professional-and-general-liability reserves, and the backdrop includes a Department of Justice criminal grand jury investigation into the acute-care line's admissions, length-of-stay, and billing practices, an $105 million jury verdict against a subsidiary this May that management is contesting, and a federal Medicaid reordering - the One Big Beautiful Bill Act - that the company says is already reducing the eligible population that pays its bills, with Medicaid representing roughly 62% of its revenue. This is a company whose operating engine is stable and healing, priced as if the legal ceiling is the story. The trade is whether the operating recovery outruns the legal and payor headwinds - and the numbers below are the clocks.